ParvOryx

ParvOryx is a drug product containing the wildtype rat oncolytic virus, parvovirus H‑1 (H‑1PV), developed for the oncolytic virotherapy of solid cancers. It selectively infects and lyses tumor cells while sparing normal cells, exerting pronounced antineoplastic effects in various preclinical and clinical models. The virus can be administered intravenously or intratumorally and is capable of crossing the blood-brain barrier. Its mechanism involves direct cytotoxicity to cancer cells—causing cell cycle arrest, transcriptional dysregulation, cellular stress response activation, and cell death—as well as induction of a strong tumor-specific immune response that transforms immunologically “cold” tumors into “hot” ones by altering their microenvironment. This leads to increased infiltration by CD8 T-cells and production of cytokines/chemokines, making tumors more susceptible to immuno-oncological therapies. Clinical trials have demonstrated safety at all dose levels with signs of efficacy in glioblastoma multiforme (GBM), metastatic pancreatic cancer, melanoma, non-small cell lung cancer (NSCLC), breast cancer, ovarian cancer (preclinical), lymphoma, pediatric tumors such as neuroblastoma and medulloblastoma, prostate cancer, renal cancer as well as tumor stem cells[2][3][5][6][7][8].

Brand names

ParvOryx

Other names

parvovirus H1wildtype rat parvovirus H1native parvovirus H-1